Literature DB >> 12598445

How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

C G Owen1, A E Fletcher, M Donoghue, A R Rudnicka.   

Abstract

AIMS: To predict the burden of blindness, partial sight, and visual impairment (binocular visual acuity 6/18 or less) due to late stage age related macular degeneration (AMD) in the ageing population of the United Kingdom.
METHODS: A systematic review, followed by a request for data, was used to establish a pooled prevalence of AMD and corresponding visual loss. Prevalence figures were applied to the UK population. Using UK population trends, the future burden of AMD over the coming decade was established.
RESULTS: Pooled data from six studies showed that the prevalence of visual loss caused by AMD increased exponentially from the age of 70-85 years of age, with 3.5% (95% CI 3.0 to 4.1) having visual impairment beyond the age of 75 years. The authors estimate that there are currently 214 000 (95% CI 151 000 to 310 000) with visual impairment caused by AMD (suitable for registration). This number is expected to increase to 239 000 (95% CI 168 000 to 346 000) by the year 2011. Currently there are 172 000 (95% CI 106 000 to 279 000) and 245 000 (95% CI 163 000 to 364 000) with geographical and neovascular AMD, respectively.
CONCLUSIONS: Estimates of visual impairment agree with official statistics for the number registered partially sighted or blind, caused by AMD, and are well below other figures often cited. Although these estimates are associated with wide confidence intervals (CI) and a number of caveats, they represent the best available data, which can be used to guide health and social care provision for older people in the UK setting. Implications for low vision services are outlined.

Entities:  

Mesh:

Year:  2003        PMID: 12598445      PMCID: PMC1771556          DOI: 10.1136/bjo.87.3.312

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  42 in total

1.  Is the incidence of registrable age-related macular degeneration increasing?

Authors:  J Evans; R Wormald
Journal:  Br J Ophthalmol       Date:  1996-01       Impact factor: 4.638

Review 2.  Epidemiology of age-related maculopathy.

Authors:  J R Vingerling; C C Klaver; A Hofman; P T de Jong
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

Review 3.  Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors.

Authors:  T Vinding
Journal:  Acta Ophthalmol Scand Suppl       Date:  1995

4.  The incidence of registered blindness caused by age-related macular degeneration.

Authors:  T Rosenberg; F Klie
Journal:  Acta Ophthalmol Scand       Date:  1996-08

Review 5.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study.

Authors:  P Mitchell; W Smith; K Attebo; J J Wang
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

6.  A prospective study of cigarette smoking and age-related macular degeneration in women.

Authors:  J M Seddon; W C Willett; F E Speizer; S E Hankinson
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

7.  A prospective study of cigarette smoking and risk of age-related macular degeneration in men.

Authors:  W G Christen; R J Glynn; J E Manson; U A Ajani; J E Buring
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

8.  Depression and disability in older people with impaired vision: a follow-up study.

Authors:  B W Rovner; P M Zisselman; Y Shmuely-Dulitzki
Journal:  J Am Geriatr Soc       Date:  1996-02       Impact factor: 5.562

Review 9.  An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group.

Authors:  A C Bird; N M Bressler; S B Bressler; I H Chisholm; G Coscas; M D Davis; P T de Jong; C C Klaver; B E Klein; R Klein
Journal:  Surv Ophthalmol       Date:  1995 Mar-Apr       Impact factor: 6.048

10.  Visual handicap in south-east Scotland.

Authors:  D D Balatsoukas; C Sioulis; A Parisi; G T Millar
Journal:  J R Coll Surg Edinb       Date:  1995-02
View more
  73 in total

1.  Smoking and blindness.

Authors:  Simon P Kelly; Judith Thornton; Georgios Lyratzopoulos; Richard Edwards; Paul Mitchell
Journal:  BMJ       Date:  2004-03-06

2.  Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration.

Authors:  Yan Lu; Yuhua Shi; Chunyan Xue; Jie Yin; Zhenping Huang
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

Review 3.  LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.

Authors:  Yu Tong; Jing Liao; Yuan Zhang; Jing Zhou; Hengyu Zhang; Meng Mao
Journal:  Mol Vis       Date:  2010-10-05       Impact factor: 2.367

Review 4.  Age-related macular degeneration and recent developments: new hope for old eyes?

Authors:  Brid Morris; Fraser Imrie; Ana-Maria Armbrecht; Baljean Dhillon
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

5.  New treatments for neovascular acute macular degeneration.

Authors:  Usha Chakravarthy; Jennifer I Lim
Journal:  BMJ       Date:  2007-02-10

6.  The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

Authors:  U Chakravarthy; M Williams
Journal:  Eye (Lond)       Date:  2013-10-25       Impact factor: 3.775

Review 7.  Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Authors:  A L Takeda; J Colquitt; A J Clegg; J Jones
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

8.  Age-related macular degeneration: current treatment and future options.

Authors:  Tanya Moutray; Usha Chakravarthy
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

9.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

10.  Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.

Authors:  D A M Lyall; A Tey; B Foot; S T D Roxburgh; M Virdi; C Robertson; C J MacEwen
Journal:  Eye (Lond)       Date:  2012-10-12       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.